香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2025年6月30日止六個月中期業績公告 財務摘要及要點 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 人民幣千元 | 人民幣千元 | % | | 收益 | 6,440,951 | 5,604,463 | 14.9 | | 毛利 | 2,172,201 | 1,848,051 | 17.5 | | 母公司擁有人應佔利潤 | 701,396 | 1,113,403 | (37.0) | | 母公司擁有人應佔非國際財務報告 | | | | | 準則經調整淨利潤 | 755,701 | 690,266 | 9.5 ...

New Stock Activities - Companies currently in the IPO process include Jiaxin International Resources, Shuangdeng Co., and Kanglong Chemical [1] - Other companies in the IPO process are Suteng Juchuang, Jinglian Group, Binjiang Services, and Yika [1] Earnings Announcement Dates - Companies scheduled to announce earnings include Tengsheng Bo Pharmaceutical-B, Chunquan Industrial Trust, and Jinchao Yang Group [1] - Additional companies include Zaitong, China Petroleum & Chemical Corporation, Jinyuan Development International Industry, and Runli Maritime [1] - Other firms set to report earnings are New Fire Technology Holdings, Weijun Group Holdings, and Citic Bank [1] Shareholder Meetings - Companies holding shareholder meetings include Wuxi Life, China Wangwang, Cultural Communication, and Jingneng Clean Energy [1] - Additional companies include GC Construction [1] Dividend Distribution - Companies declaring dividends include Huixian Industrial Trust, Cabin, and Baotan Holdings [1] - Other firms include Pacific Shipping, China New Town, and Victory Securities [1] - Additional companies declaring dividends are Jinsang Machine Tool China, Aihua Credit, and Gaoxin Retail [1] - First Service Holdings is also listed for dividend distribution [1] Dividend Payment Dates - Companies with scheduled dividend payment dates include Midea Real Estate, China Galaxy, CITIC Securities, and China Life [2]

Market Overview - The Hong Kong stock market experienced a slight decline on August 19, with the Hang Seng Index falling by 0.21% to 25,122.90, the Hang Seng China Enterprises Index down by 0.30% to 9,006.23, and the Hang Seng Tech Index decreasing by 0.67% to 5,542.03, indicating a relatively stable overall sentiment [1][2]. Sector Performance - Major technology stocks mostly declined, with significant drops in the film and television sector, semiconductor stocks, Chinese brokerage firms, rare earth concept stocks, innovative pharmaceuticals, gold stocks, and brain-computer interface concept stocks. Notably, the live-streaming stock Dongfang Zhenxuan plummeted nearly 21% [2][3]. - The property management sector showed strength throughout the day, while consumer sectors such as restaurants and sports goods performed actively [2][3]. Individual Stock Movements - Major tech stocks like NetEase and Xiaomi fell by 1.2% and 1.23% respectively, while Meituan and JD.com also saw slight declines. Tencent and Kuaishou experienced minor increases [4][5]. - Semiconductor stocks faced significant declines, with SMIC and Hua Hong Semiconductor dropping over 3%. However, a report from Tianfeng Securities suggests a positive outlook for global semiconductor growth driven by AI by 2025 [5][6]. - The pharmaceutical outsourcing sector saw substantial losses, with Tigermed down over 8% and other companies like WuXi AppTec and Zai Lab also declining significantly [7][8]. - Chinese brokerage stocks fell, with Xingsheng International down over 6% and other major firms like China International Capital Corporation and Shenwan Hongyuan also experiencing declines. However, there are indications of improving liquidity in the securities market, which could benefit brokerage firms [8]. Gold and Precious Metals - Gold and precious metals stocks declined, with companies like Chifeng Jilong Gold and Lingbao Gold dropping over 3%. Market sentiment is influenced by expectations surrounding the Federal Reserve's policy direction and geopolitical developments [8][9]. Property Management and Consumer Sectors - The property management sector saw notable gains, with Wanwu Cloud rising over 7% and other firms like Zhengrong Service and Rongchuang Service also increasing by more than 5%. This is supported by government measures to stabilize the real estate market [9][10]. - The restaurant sector experienced significant gains, with Daoxiang Holdings up over 11% and other companies like Xiaocaiyuan and Haidilao also showing positive performance [11]. Capital Inflows - Southbound funds recorded a net inflow of 18.573 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 8.911 billion HKD and the Shenzhen-Hong Kong Stock Connect adding 9.662 billion HKD [14]. Market Sentiment - Huatai Securities noted that the Hong Kong stock index has been fluctuating but is on an upward trend, with increased volatility. The market is currently in a critical phase awaiting verification of significant domestic and international events, suggesting a window for position adjustments [16].

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies saw the largest increases and decreases in ownership percentages. Group 1: Companies with Increased Holdings - Zhengzhou Bank (06196) saw the largest increase in holdings, up by 2.16% to a total holding of 53.89% [1][2] - Kanglong Chemical (03759) increased by 1.35%, reaching a holding of 56.80% [1][2] - Weimob Group (02013) rose by 1.22%, with a current holding of 32.63% [1][2] - Other notable increases include Longi Green Energy (06869) at +1.00% (56.28%) and Junshi Biosciences (01877) at +0.87% (55.48%) [2][3] Group 2: Companies with Decreased Holdings - Heng Seng China Enterprises (02828) experienced the largest decrease, down by 8.07% to a holding of 0.85% [1][2] - The Yingfu Fund (02800) decreased by 4.21%, now at 0.68% [1][2] - Delin Holdings (01709) saw a reduction of 3.04%, with a holding of 23.31% [1][2] - Other significant decreases include Kylin Holdings (06821) at -4.76% (46.29%) and Dongyang Sunshine Pharmaceutical (06887) at -4.22% (48.82%) [3][4] Group 3: Five-Day Changes - Longi Green Energy (06869) had the highest five-day increase at +5.78%, with a holding of 56.28% [3][4] - Delin Holdings (01709) increased by 4.74% to 23.31% [3][4] - Lens Technology (06613) rose by 3.84%, reaching 5.97% [3][4] Group 4: Twenty-Day Changes - Longi Green Energy (06869) also led in the twenty-day increase with +25.78%, holding 56.28% [4] - Other notable increases include Dongfang Electric (01072) at +11.23% (38.53%) and China Energy Construction (03996) at +10.76% (20.18%) [4]

Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index on August 14, highlighting the stock price movements of Kanglong Chemical, a key player in the life sciences industry, and its A/H share premium status [1]. Group 1: Market Performance - On August 14, the Shanghai Composite Index fell by 0.46%, closing at 3666.44 points, while the Hang Seng Index decreased by 0.37%, closing at 25519.32 points [1]. Group 2: Company Overview - Kanglong Chemical (stock code: 300759.SZ/3759.HK) is a major service provider in the life sciences sector, established in 2004. The company has invested in talent and facilities, developing extensive research, development, and production capabilities across drug discovery, preclinical, and clinical development [1]. - The company offers a range of therapeutic approaches, including small molecules, biologics, and CGT products, and has a strong track record in providing R&D solutions for partners in North America, Europe, Japan, and China [1]. Group 3: A/H Share Premium - Kanglong Chemical's A/H share premium reached 46.69%, ranking it 74th among A/H shares. As of the close, the A-share price was 30.17 yuan, down by 2.17%, while the H-share price was 22.5 Hong Kong dollars, up by 1.26% [1].

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris (up 12.83% to HKD 2.11), Zhaoyan New Drug (up 9.23% to HKD 24.62), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September, indicating a recovery trend in overall investment and financing [2] - The domestic market for preclinical CRO, clinical CRO, and CDMO services has stabilized in pricing, with a steady recovery in new orders expected to lead to an industry turnaround [2] - Internationally, the CDMO pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed, suggesting a positive trend for overseas orders [2]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris Bio (+12.83%), Zhaoyan New Drug (+9.23%), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September [2] - Overall investment and financing trends are showing signs of recovery, with prices for preclinical CRO, clinical CRO, and CDMO services stabilizing [2] - The international CDMO business maintains a reasonable pricing structure, with the impact of high pandemic baselines now absorbed [2]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of August 12, 2025, the latest net value of the fund is 1.9165 yuan, reflecting a decrease of 0.56%. The fund's one-month return is 7.20%, six-month return is 23.93%, and year-to-date return is 22.17% [1] - The fund's top ten stock holdings account for a total of 54.73%, with notable positions in WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) among others [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of June 30, 2025, it has a total scale of 15.638 billion yuan [1] - The fund is managed by two key individuals: Ms. Ge Lan, who has been the fund manager since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Core Viewpoint - Kanglong Chemical announced the approval of a capital increase and amendments to its articles of association during the shareholder meetings held on June 20, 2025 [1] Group 1 - The company completed the necessary business registration changes and obtained a new business license from the Beijing Economic and Technological Development Zone Market Supervision Administration [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 6 月 20 日召开的 2024 年年度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会审议通 ...